comparemela.com

Latest Breaking News On - Tubuli board - Page 1 : comparemela.com

DGAP-News: Andera Partners supports Tubulis in a €60 million Series B financing to accelerate the development of its ADCs

DGAP-News: Andera Partners / Key word(s): Financing Andera Partners supports Tubulis in a €60 million Series B financing to accelerate the development of its ADCs 03.05.2022 / 11:05

DGAP-News: Andera Partners supports Tubulis in a €60 million Series B financing to accelerate the development of its ADCs

DGAP-News: Andera Partners / Key word(s): Financing Andera Partners supports Tubulis in a €60 million Series B financing to accelerate the development of its ADCs 03.05.2022 / 11:05 The issuer is solely responsible for the content of this announcement. Press Release Andera Partners supports Tubu.

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing investors

Tubulis Closes €60M Series B Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Tubulis Appoints Christian Grøndahl as Independent Chairman to Lead Supervisory Board

Tubulis Appoints Christian Grøndahl as Independent Chairman to Lead Supervisory Board Tubulis today announced the appointment of Dr. Christian Grøndahl, as the inaugural Chairman of the company s Supervisory Board. As an experienced biotech executive and company founder, Dr. Grøndahl has an established track record in advancing early-stage biotech innovations and distinguished technology platforms into valuable products and medicines. His leadership will be fundamental to shaping Tubulis as it designs and moves its novel antibody-drug conjugates (ADCs) toward clinical evaluation to improve cancer treatments and further establishes itself as an up-and-coming leader in the oncology and ADC drug development field.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.